Physician profile
David L Hei
NPI 1851368476
$2,111.79
in general payments reported to CMS, 2019-2025
21 companies · $25.00 in 2025
The $25.00 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $97.98 · 2021: $1,017 · 2022: $488 · 2023: $288 · 2025: $25.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $167 · Education: $124 · Food and Beverage: $22.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $124.00 |
| Food and Beverage | $22.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,465.18 | 2021-2023 | |
| Janssen Biotech, INC. | $214.78 | 2019-2023 | Erleada |
| Pfizer INC. | $55.35 | 2019-2022 | |
| Incyte Corporation | $43.06 | 2019-2022 | |
| Daiichi Sankyo INC. | $35.03 | 2020 | |
| Seagen INC. | $29.21 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $26.12 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.02 | 2019 | |
| Genmab U.S., INC. | $25.00 | 2025 | Epkinly |
| Hologic Sales and Service, LLC | $22.43 | 2023 | Aptima, Thinprep 2000 Processor |
| Genentech USA, INC. | $21.24 | 2020 | |
| Celgene Corporation | $17.89 | 2019 | |
| Lilly USA, LLC | $17.62 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $16.77 | 2019 | |
| Abbvie INC. | $16.51 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $15.10 | 2022 | |
| Merck Sharp & Dohme LLC | $13.48 | 2019 | |
| Glaxosmithkline, LLC. | $13.36 | 2021 | |
| Taiho Oncology, INC. | $13.02 | 2019 | |
| Eisai INC. | $12.70 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.